CASE REPORT

An autopsy-proven case of Corticobasal degeneration heralded by Pontine infarction

Dallah Yoo, Sung-Hye Park, Sungwook Yu and Tae-Beom Ahn

Abstract

Background: Neurodegenerative disorders are characterized by insidious progression with poorly-delineated long latent period. Antecedent clinical insult could rarely unmask latent neurodegenerative disorders. Here, we report an autopsy-proven case of corticobasal degeneration which was preceded by a lacunar infarction.

Case presentation: A 58-year-old man presented with acute ataxia associated with a lacunar infarction in the right paramedian pons. His ataxia persisted with additional progressive gait difficulty and left arm clumsiness. Six months later, a follow-up neurological examination showed asymmetrical bradykinesia, apraxia, dystonic posturing, postural instability, and mild ataxia of the left limbs. Cognitive examination revealed frontal executive dysfunction and visuospatial difficulties. Dopamine transporter imaging scan demonstrated bilateral reduced uptakes in mid-to-posterior putamen, more prominent on the right side. Levodopa-unresponsive parkinsonism, asymmetric limb dystonia, and ideomotor apraxia became more conspicuous, while limb ataxia gradually vanished. The patient became unable to walk without assistance after 1 year, and died 4 years after the symptom onset. Autopsy findings showed frontoparietal cortical atrophy, ballooned neurons, and phosphorylated tau-positive astrocytic plaques and neuropol threads with gliosis and neuronal loss, confirming the corticobasal degeneration.

Conclusions: The case illustrates that precedent clinical events such as stroke might tip a patient with subclinical CBS into overt clinical manifestations.

Keywords: Corticobasal degeneration, Stroke, Autopsy, Case report

Background

Corticobasal degeneration (CBD) is a pathologic entity characterized by widespread tau-immunoreactive deposits in neurons and glia with a specific topographical distribution [1]. The clinical presentation of CBD is a variable combination of asymmetrical akinetic-rigid syndrome, ideomotor limb apraxia, and other clinical features including cortical sensory deficits, dystonic posturing, myoclonus, and cognitive impairment [2]. Although clinical phenotypes of CBD are heterogeneous in clinicopathologic studies, none has been reported clinical evolution of CBD consecutive to precedent non-neurodegenerative event [3]. Here, we report an autopsy-proven case of CBD which was preceded by a lacunar infarction.

Case presentation

A 58-year-old right-handed man visited our hospital because of acute development of incoordination of gait and left limbs. Neurological examination showed left limb ataxia with an acute paramedian pontine infarction in brain magnetic resonance imaging (Fig. 1a to b; diffusion-weighted and fluid-attenuated inversion recovery imaging, respectively). He was an ex-smoker and had...
no hypertension and diabetes mellitus. For the next six months, he was treated with antiplatelet but had complained progressive gait difficulty and aggravated dexterity of his left limbs. A follow-up neurological examination showed asymmetrical bradykinesia, apraxia, dystonic posturing, postural instability, and ataxia of the left limbs (Supplementary Video, Part A). Cognitive function was impaired with a Korean version of the Mini-Mental Status Examination score of 21/30 and a Frontal Assessment Battery score of 8/18. Positron emission tomography using $^{18}$F-N-3-fluoropropyl-2β-carboxymethoxy-3β-(4-iodophenyl)-nortropane showed decreased dopamine transporter uptake (Fig. 1).
bindings in both mid-to-posterior putamen, more apparent on the right side (Fig. 1c). Levodopa was ineffective up to 600 mg per day. Left-limb dystonia and apraxia became more conspicuous, while limb ataxia vanished. The patient was unable to walk without assistance one year later. (Supplementary Video, Part B) and died four years after the onset.

On autopsy, gross examination showed cortical atrophy in the parietal and frontal lobes. Microscopic examination of the medial pontine lesion of the lacunar infarct showed tissue loss with remnant blood vessels (Fig. 1d, arrow on the brain slice, Haemotoxylin and Eosin, (H&E)). Astrocyte plaques and coiled bodies were found in ballooned neurons, gliosis, and neuronal loss in the parietal lobe, motor cortex, cingulate gyrus, and hippocampus (Fig. 1e, h&e). Phosphorylated tau-positive neurit threads and astrocytic plaques were found in the frontoparietal lobes, cingulate gyrus, hippocampus, basal ganglia, thalamus, brainstem, and cerebellum (Fig. 1f, AT8). There were no inclusions stained with antibodies against β-amyloid, α-synuclein, or TAR DNA binding protein 43(TDP-43).

**Discussion and conclusions**

Clinical features are summarized as acute pontine infarction and later presentation of levodopa-unresponsive asymmetric parkinsonism, dystonia, and apraxia, which are compatible with the clinical diagnosis of CBD [2].

It is worth noticing the initial presence of cerebellar ataxia. To our knowledge, there was only one case with pathologically confirmed CBD with prominent cerebellar ataxia in which TDP-43 co-existed [4]. In our case, ataxia developed as a clinical manifestation of acute pontine infarction rather than a de novo contribution of CBD. The rapid evolution of CBD, provoked by the preceding infarction, replaced ataxia with dystonia.

The mechanism of CBD flare-up after cerebral infarction remains speculative. It is more likely that aberrant pathologic network associated with tau-related neurodegeneration in CBD have constructed for years before the presentation. According to the model of cortico-basal ganglia-cerebellar connectome, an acute infarction in the pons could be detrimental to subclinical aberrant network responsible for CBD, turning latent abnormalities into clinical manifestation [5]. Alternatively, it was reported that tau protein increased in the cerebrospinal fluid after acute ischemic stroke [6]. Increased burden of tau might have provided a link between the infarction and CBD.

In the case of Parkinson’s disease (PD), some clinical events such as subdural hematoma or the use of dopamine receptor blocking agents could uncover latent PD [7]. In CBD, this is the first autopsy-confirmed CBD case unmasked by precedent cerebral infarction.

---

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12883-021-02178-9.

**Additional file 1.**

**Abbreviations**

CBD: Corticobasal Degeneration; TDP-43: TAR DNA binding protein-43; H&E: Haemotoxylin and Eosin; PD: Parkinson’s disease

**Acknowledgements**

We appreciate the patient and his family for their contribution to this report.

**Authors’ contributions**

SY and TA recruited the patient and dealt with the acquisition and interpretation of data; SP performed and interpreted the pathologic examinations; DY wrote the first draft of the manuscript; TA reviewed the literature and critically revised the draft; The authors read and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article.

**Declarations**

**Ethics approval and consent to participate**

The autopsy was permitted by his family members and conducted under the approved protocol by local ethics committee (Seoul National University Hospital).

**Consent for publication**

The study has been conducted in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki), the informed consent from the patient to participate in the study was waived by local ethics committee (Kyung Hee University Hospital), and the written consent for publication was obtained from the kin of the patient.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Neurology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.
2. Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
3. Department of Neurology, Korea University Hospital, Korea University College of Medicine, Seoul, South Korea.

Received: 13 December 2020 Accepted: 29 March 2021

Published online: 06 April 2021

**References**

1. Dickson DW, Bergeron C, Chin SS, Duynjakaerts C, Horoupian D, Ikeda K, et al. Office of Rare Diseases Neuropathologic Criteria for Corticobasal degeneration. J Neuropathol Exp Neurol. 2002;61(11):935–46. https://doi.org/10.1093/jnen/61.11.935.
2. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borrini B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2012;80(5):496–503. https://doi.org/10.1212/wnl.0b013e318270fd1.
3. Litvan I, Agid Y, Goutz C, Jankovic J, Wenning GK, Brandel JP, et al. Accuracy of the clinical diagnosis of Corticobasal degeneration. A Clinico-pathologic Study. 1997;48(1):119–25. https://doi.org/10.1212/wnl.48.1.119.
4. Kouri N, Oshima K, Takahashi M, Murray ME, Ahmed Z, Parisi JE, et al. Corticobasal degeneration with olivopontocerebellar atrophy and TDP-43 pathology: an unusual clinicopathologic variant of CBD. Acta Neuropathol. 2013;125(5):741–52. https://doi.org/10.1007/s00401-013-1087-8.
5. Quartarone A, Cacciola A, Milardi D, Ghilardi MF, Calamuneri A, Chillemi G, et al. New insights into cortico-basal-cerebellar connectome: clinical and physiological considerations. Brain. 2019;143(2):396–406. https://doi.org/10.1093/brain/awz310.

6. Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P, et al. Cerebrospinal fluid markers for Alzheimer’s disease evaluated after acute ischemic stroke. J Alzheimers Dis. 2000;2(3–4):199–206. https://doi.org/10.3233/jad-2000-23-402.

7. Diaz-Corrales FJ, Sanz-Viedma S, Garcia-Solis D, Escobar-Delgado T, Mir P. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2010;37(3):556–64. https://doi.org/10.1007/s00259-009-1289-4.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.